SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN-502, A POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST

Abstract

Frederick A. Schmitt, Stephanie Sherman, Brian G. Skotko, Amy L. Talboy, Jason Woodward, Howard H. Feldman, Carolyn Revta, Kimberly A. Schafer, Hampus Hillerstrom, William Mobley, LuMind RDS Foundation, Burlington, MA, USA; Banner Alzheimer’s Institute, Phoenix, AZ, USA; Down Syndrome Clinic and Research Center, Kennedy Krieger Institute, Baltimore, MD, USA; Advocate Medical Group Adult Down Syndrome Center, Advocate Lutheran General Hospital, Park Ridge, IL, USA; Case Western Reserve University School of Medicine, Cleveland, OH, USA; Jane and Richard Thomas Center for Down Syndrome, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; Duke University Medical Center, Durham, NC, USA; Gillespie Neuroscience Research Facility, University of California Irvine, Irvine, CA, USA; Massachusetts General Hospital, Boston, MA, USA; McLean Hospital, Belmont, MA, USA; Harvard Medical School, Boston, MA, USA; University of California, Irvine School of Medicine, Irvine, CA, USA; Rush University Medical Center, Chicago, IL, USA; Harvard Medical School, Boston, MA, USA; Emory University School of Medicine, Atlanta, GA, USA; Down Syndrome Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Sanders-Brown Center on Aging Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY, USA; University of California San Diego, La Jolla, CA, USA; University of California, San Diego, La Jolla, CA, USA; Alzheimer’s Disease Cooperative Study, University of California, San Diego, La Jolla, CA, USA. Contact e-mail: [email protected]